Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
-
Immune Profile Of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities For T-cell Directed Immunotherapy
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to evaluate immune profile of Acute Myeloid Leukemia (AML) patients receiving Venetoclax plus Azacitidine induction chemotherapy.
-
MC230818 Understanding The Mechanisms Of Clonal And Non-Clonal Cytopenia Following CAR-T Therapy
Albert Lea, MN
Scottsdale/Phoenix, AZ
Eau Claire, WI
Jacksonville, FL
La Crosse, WI
Mankato, MN
Rochester, MN
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.
Closed for Enrollment
-
A Phase 1 First In Human Study Of The Menin-MLL(KMT2A) Inhibitor KO 539 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine the maximum tolerated dose (MTD) of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed acute myeloid leukemia (AML) who have failed or are ineligible for any approved standard of care therapies, including hematopoietic stem cell transplantation (HSCT).
-
A Phase 1, Multi-center, Open-label, Dose Finding Study Of CC-96191 In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia
Jacksonville, FL
Rochester, MN
The purpose of this study is to explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and effectiveness of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
-
A Phase 2 Study Of Donor-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-401) Administered To Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation (ARTEMIS)
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate safety and effectiveness of MT-401 administration to patients with AML, who have received their first allogeneic HSCT.
-
A Phase Ia/Ib Study Of NMS-03597812 In Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Including Patients With TP53 Mutations
Rochester, MN
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.
-
A Randomized, Open Label Phase 3 Study Evaluating Safety And Efficacy Of Venetoclax In Combination With Azacitidine After Allogeneic Stem Cell Transplantation In Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)
Jacksonville, FL
Rochester, MN
The main objective of this study is to evaluate the effectiveness of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in AML patients compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT). This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the effectiveness and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).
**Please note that at Mayo Clinic, this study will only be enrolling in Part 2 of the trial and will not be enrolling adolescents. We will be enrolling adult subjects only.
-
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study To Evaluate The Efficacy, Safety And Tolerability Of Axatilimab At 3 Different Doses In Patients With Recurrent Or Refractory Active Chronic Graft Versus Host Disease Who Have Received At Least 2 Lines Of Systemic Therapy
Jacksonville, FL
Rochester, MN
The purpose of this study is to assess SNDX-6352, or Axatilimab, for individuals who have active chronic recurrent or refractory Graft versus Host Disease (cGVHD) whom have used at least two previous treatments and have not had an improvement in symptoms. This study evaluates the effectiveness, safety, and tolerability of axatilimab at three different dose levels. Participants can receive axatilimab for up to two years and could be in the study up to 28 months.
-
Randomized Trial Of Gilteritinib Vs Midostaurin In FLT3 Mutated Acute Myeloid Leukemia (AML)
Jacksonville, FL
Rochester, MN
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML.
.